Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy

Pascal Buijs, Geert Amerongen, Stefan van Nieuwkoop, Theo Bestebroer, Peter van Run, Thijs Kuiken, Ron Fouchier, Casper van Eijck, BG van den Hoogen

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)

Abstract

Newcastle disease virus (NDV) is an avian pararnyxovirus with oncolytic potential. Detailed preclinical information regarding the safety of Oncolytic NDV is scarce. In this study, we evaluated the toxicity, biodistribution and shedding of intravenously injected oncolytic NDVs in non-human primates (Macaca fascicularis). Two animals were injected with escalating doses of a non-recombinant Vaccine strain, a recombinant lentogenic strain or a recombinant mesogenic strain. To study transmission, naive animals: were co-housed with the injected animals. Injection with NDV did not lead to severe illness in the animals or abnormalities in hematologic or biochemistry Measurements. Injected animals shed low amounts of virus, but this did not lead to seroconversion of the contact animals. Postmortem evaluation demonstrated no pathological changes or evidence of virus replication. This study demonstrates that NDV generated in embryonated chicken eggs is safe for intravenous administration to non-human primates. In addition, our study Confirmed results from a previous report that naive primate and human sera are able to neutralize egg-generated NDV. We discuss the implications of these results for our study and the Use of NDV for virotherapy.
Original languageUndefined/Unknown
Pages (from-to)463-471
Number of pages9
JournalCancer Gene Therapy
Volume21
Issue number11
DOIs
Publication statusPublished - 2014

Cite this